Table 4.

Treatment-emergent AEs leading to dose interruption/reduction and treatment discontinuation

Preferred term, unless noted otherwise	N = 725 n (%)
AE leading to dose interruption/reduction in ≥1% of patients
Any AE	262 (36.1)
Thrombocytopenia	76 (10.5)
Infections and infestations (SOC)∗	51 (7.0)
Nausea	15 (2.1)
Diarrhea	14 (1.9)
Anemia	12 (1.7)
Neutropenia	12 (1.7)
Asthenia	11 (1.5)
Headache	11 (1.5)
Alanine aminotransferase increased	9 (1.2)
Atrial fibrillation	8 (1.1)
Fatigue	8 (1.1)
Platelet count decreased	8 (1.1)
AE leading to momelotinib discontinuation in ≥1% of patients
Any AE	229 (31.6)
Infections and infestations (SOC)†	29 (4.0)
Thrombocytopenia	27 (3.7)
Peripheral sensory neuropathy	13 (1.8)
Acute myeloid leukemia	11 (1.5)
Disease progression	11 (1.5)
Diarrhea	8 (1.1)
Anemia	7 (1.0)
Splenomegaly	7 (1.0)

^∗Includes preferred term pneumonia (n = 15; 2.1%).

^†Includes preferred term pneumonia (n = 8,;1.1%).